Citicoline and COVID-19: vis-à-vis conjectured

Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barri...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-kuraishy, Hayder M., Al-Buhadily, Ali K., Al-Gareeb, Ali I., Alorabi, Mohammed, Hadi Al-Harcan, Nasser A., El-Bouseary, Maisra M., Batiha, Gaber El-Saber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442587/
https://www.ncbi.nlm.nih.gov/pubmed/36063198
http://dx.doi.org/10.1007/s00210-022-02284-6
_version_ 1784782848385875968
author Al-kuraishy, Hayder M.
Al-Buhadily, Ali K.
Al-Gareeb, Ali I.
Alorabi, Mohammed
Hadi Al-Harcan, Nasser A.
El-Bouseary, Maisra M.
Batiha, Gaber El-Saber
author_facet Al-kuraishy, Hayder M.
Al-Buhadily, Ali K.
Al-Gareeb, Ali I.
Alorabi, Mohammed
Hadi Al-Harcan, Nasser A.
El-Bouseary, Maisra M.
Batiha, Gaber El-Saber
author_sort Al-kuraishy, Hayder M.
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19.
format Online
Article
Text
id pubmed-9442587
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-94425872022-09-06 Citicoline and COVID-19: vis-à-vis conjectured Al-kuraishy, Hayder M. Al-Buhadily, Ali K. Al-Gareeb, Ali I. Alorabi, Mohammed Hadi Al-Harcan, Nasser A. El-Bouseary, Maisra M. Batiha, Gaber El-Saber Naunyn Schmiedebergs Arch Pharmacol Review Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19. Springer Berlin Heidelberg 2022-09-05 2022 /pmc/articles/PMC9442587/ /pubmed/36063198 http://dx.doi.org/10.1007/s00210-022-02284-6 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Al-kuraishy, Hayder M.
Al-Buhadily, Ali K.
Al-Gareeb, Ali I.
Alorabi, Mohammed
Hadi Al-Harcan, Nasser A.
El-Bouseary, Maisra M.
Batiha, Gaber El-Saber
Citicoline and COVID-19: vis-à-vis conjectured
title Citicoline and COVID-19: vis-à-vis conjectured
title_full Citicoline and COVID-19: vis-à-vis conjectured
title_fullStr Citicoline and COVID-19: vis-à-vis conjectured
title_full_unstemmed Citicoline and COVID-19: vis-à-vis conjectured
title_short Citicoline and COVID-19: vis-à-vis conjectured
title_sort citicoline and covid-19: vis-à-vis conjectured
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442587/
https://www.ncbi.nlm.nih.gov/pubmed/36063198
http://dx.doi.org/10.1007/s00210-022-02284-6
work_keys_str_mv AT alkuraishyhayderm citicolineandcovid19visavisconjectured
AT albuhadilyalik citicolineandcovid19visavisconjectured
AT algareebalii citicolineandcovid19visavisconjectured
AT alorabimohammed citicolineandcovid19visavisconjectured
AT hadialharcannassera citicolineandcovid19visavisconjectured
AT elbousearymaisram citicolineandcovid19visavisconjectured
AT batihagaberelsaber citicolineandcovid19visavisconjectured

Ejemplares similares